Free Gastroenterology CME

Activity Description / Statement of Need:

In this online, self-learning activity:

Thymidine kinase 2 deficiency (TK2D) is an ultrarare mitochondrial disease caused by recessive mutations in the TK2 gene and manifesting as a form of mitochondrial DNA depletion/deletion syndrome (MDDS) and mitochondrial myopathy. Under normal conditions, the TK2 gene encodes for the thymidine kinase enzyme present in the mitochondria, which is responsible for the phosphorylating of pyrimidine nucleosides, deoxythymidine, and deoxycytidine. These are the first steps in mitochondrial DNA synthesis, and researchers speculate that TK2 mutations affect muscle tissue because its higher energy demands make it most susceptible to mitochondrial impairment. Mutational analyses of patients with MDDS have found that approximately 15% have TK2 mutations, which may be extrapolated to about 600 to 2,700 individuals in the US.

Target Audience:

HCPs including but not limited to: neurologists, pediatric neurologists, pediatricians, primary care providers, pulmonologists, gastroenterologists, and medical geneticists; physician assistants, nurse practitioners, pharmacists, and nurses who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with TK2D.

HCC in the Real World: Evolving Paradigms for High-Risk Patients is a CME activity designed for US-based medical oncologists, gastrointestinal oncologists, hepatologists, gastroenterologists, advanced practice providers, nurses, and other healthcare professionals involved in the treatment and collaborative management of hepatocellular carcinoma (HCC). This educational initiative focuses on the evolving role of frontline immune checkpoint inhibitor (ICI)-based therapies, with emphasis on applying recent prospective data in higher-risk patient populations. Learners will enhance their ability to integrate liver reserve assessment with tumor burden and mortality risk to individualize treatment selection and monitoring, while also strengthening shared decision-making strategies that incorporate patient-specific clinical and functional factors to optimize frontline ICI therapy outcomes in HCC.

This MedHive™ workshop convenes expert faculty in a case-based, peer-driven format to help interprofessional teams individualize hepatocellular carcinoma (HCC) treatment while preserving hepatic reserve and quality of life. Faculty will translate clinical trial and real-world evidence into practical selection among immune checkpoint inhibitor (ICI)–based regimens for advanced disease, including in patients with impaired liver function or other high-risk features. Throughout, faculty will model multidisciplinary coordination, shared decision-making, and structured monitoring of liver function and treatment-related toxicity across the care continuum.

Advancing the Pediatric to Adult Continuum in IBS-C: Evidence-Based Treatment and Transitions of Care is a continuing medical education (CME) activity designed for US-based pediatric and adult gastroenterologists, nurse practitioners, physician assistants, GI nursing professionals, transition coordinators, and behavioral health specialists involved in the care of patients with IBS-C. This activity focuses on applying evidence-based approaches to the selection, initiation, dosing, and monitoring of newly approved and emerging therapeutic agents in pediatric patients aged 7 to 17 years, including effective management of adverse effects. In addition, it will provide learners with a structured framework to support safe and effective transition of adolescents with IBS-C to adult care, emphasizing readiness assessment, care coordination, and continuity of medication therapy to optimize long-term patient outcomes.